Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
Inventors
SONG, Colette • Schoor, Oliver • FRITSCHE, Jens • Weinschenk, Toni • Singh, Harpreet
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12247057-B2
Publication Date
2025-03-11
Expiration Date
Abstract
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Core Innovation
The invention relates to lung-cancer immunotherapy peptide sets and peptide variants, including cross-reactive homologs, that bind MHC class I and may include elongated forms for MHC class II. The peptides are provided as specific peptide sequences, identified by SEQ ID NO: 1-489, and are presented with coverage across HLA alleles. The described antigen concept is centered on tumor-associated T-cell epitope peptides and their variant forms for immune targeting in lung cancer.
The invention addresses the problem of identifying and using tumor-associated T-cell epitope peptides and their variants for lung-cancer immunotherapy, including peptides that fit defined HLA allele coverage and can be recognized through MHC-associated presentation. The partial content indicates use of identification and mapping approaches that connect peptide targets to HLA ligand findings, including references to LC-MS and a pipeline for TUMAP identification. This supports selecting peptide targets and variants relevant to lung cancer.
Beyond peptide sequences, the invention is directed to multiple therapeutic formats for delivering and targeting the peptide-MHC epitope concept. These formats include nucleic acids and expression vectors, antigen-presenting cells such as dendritic cells, activated CD4/CD8 T cells, TCRs including soluble TCR and cloned TCRs, and antibodies targeting peptide-MHC complexes. Biomarker and diagnostic concepts are also referenced through peptide/target over-presentation or over-expression and HLA allele coverage.
Claims Coverage
The provided independent claims are clm-00001 and clm-00014. Across these independent claims, the inventive coverage focuses on two inventive features: a specific peptide sequence in pharmaceutically acceptable salt form and a pegylated version of that peptide sequence.
Defined peptide sequence in pharmaceutically acceptable salt form
A peptide consisting of the amino acid sequence QENSYQSRL (SEQ ID NO: 477) in the form of a pharmaceutically acceptable salt.
Pegylated defined peptide sequence
A pegylated peptide consisting of the amino acid sequence of QENSYQSRL (SEQ ID NO: 477) or a pharmaceutically acceptable salt thereof.
The independent claims cover a specific peptide sequence as a pharmaceutically acceptable salt and a pegylated version of that peptide sequence, with the remaining inventive scope in the provided dependents directed to salt type, immunologically relevant context, and pharmaceutical composition elements such as carriers and optionally listed adjuvants.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?